| |
Latest 10 SEC filings (by transaction date) for LRMR within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Feb 16/24 | Feb 16/24 | Flynn James E | Indirect Ownership | Common Stock | P - Open market or private purchase | 1,430,205 | $8.74 |
Feb 16/24 | Feb 16/24 | Flynn James E | Indirect Ownership | Common Stock | P - Open market or private purchase | 1,430,206 | $8.74 |
Feb 16/24 | Feb 16/24 | Flynn James E | Indirect Ownership | Common Stock | P - Open market or private purchase | 1,430,206 | $8.74 |
Feb 15/24 | Feb 14/24 | Thomas Frank E | Direct Ownership | Common Stock | P - Open market or private purchase | 2,000 | $11.00 |
Jan 19/24 | Jan 17/24 | Shankar Gopi | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 135,000 | |
Jan 19/24 | Jan 17/24 | Shankar Gopi | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 22,500 | |
Jan 19/24 | Jan 17/24 | Celano Michael | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 187,500 | |
Jan 19/24 | Jan 17/24 | Celano Michael | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 31,250 | |
Jan 19/24 | Jan 17/24 | Clayton Russell | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 135,000 | |
Jan 19/24 | Jan 17/24 | Clayton Russell | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 22,500 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for LRMR within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Feb 16/24 | Feb 16/24 | Flynn James E | Indirect Ownership | Common Stock | P - Open market or private purchase | 1,430,205 | $8.74 |
Feb 16/24 | Feb 16/24 | Flynn James E | Indirect Ownership | Common Stock | P - Open market or private purchase | 1,430,206 | $8.74 |
Feb 16/24 | Feb 16/24 | Flynn James E | Indirect Ownership | Common Stock | P - Open market or private purchase | 1,430,206 | $8.74 |
Feb 15/24 | Feb 14/24 | Thomas Frank E | Direct Ownership | Common Stock | P - Open market or private purchase | 2,000 | $11.00 |
Jan 19/24 | Jan 17/24 | Shankar Gopi | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 135,000 | |
Jan 19/24 | Jan 17/24 | Shankar Gopi | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 22,500 | |
Jan 19/24 | Jan 17/24 | Celano Michael | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 187,500 | |
Jan 19/24 | Jan 17/24 | Celano Michael | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 31,250 | |
Jan 19/24 | Jan 17/24 | Clayton Russell | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 135,000 | |
Jan 19/24 | Jan 17/24 | Clayton Russell | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 22,500 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Cerevel Therapeutics Hold (OQ:CERE) |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |